KPV

researchImmune/Anti-inf

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeAnti-inflammatory / GI

MechanismTripeptide from α-MSH pathway; experimental anti-inflammatory effects

EffectsTripeptide from α-MSH pathway; experimental anti-inflammatory effects

DosingNo human dose established.

Bottom linePopular in research/compounding; human safety/benefit not well-established.

Protocols · as published1 sourced

Community protocol — not clinically establishedCommunity guide

RouteSubcutaneous or oral

FrequencySC often once daily; oral once or twice daily

StartingNot separately stated

EscalationNot stated

Target200-500 mcg

"No completed human dose-finding trial defines an official KPV protocol." Oral figures are extrapolated from mouse colitis work.

Sourcepeptidedosingprotocols.com ↗

Batches on file1

80 mgblend · JA-102113 · 2026-01no purity figure

Read with10

Semaglutide Tirzepatide Liraglutide Exenatide Dulaglutide Pramlintide Cagrilintide Retatrutide Leptin / Metreleptin Glucagon

Cautions & interactions

Not FDA-approved; unknown risks

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.